9119 POSTER Combination of Pertuzumab and Erlotinib as 2nd-/3rd-Line (2/3L) Treatment for Patients (pts) With Metastatic Non-Small Cell Lung Cancer (NSCLC) – Safety and Anti-Tumour Activity by FDG-PET/CT Imaging Changes

Saved in:

Bibliographic Details
Published in	European journal of cancer (1990) Vol. 47; p. S629
Main Authors	Hughes, B, Mileshkin, L, Townley, P, Gitlitz, B, Eaton, K, Mitchell, P, Hicks, R, Loecke, D, Amler, L, Pirzkall, A
Format	Journal Article
Language	English
Published	Elsevier Ltd 2011
Subjects	Hematology, Oncology and Palliative Medicine
Online Access	Get full text

Loading…

More Information
ISSN:	0959-8049 1879-0852
DOI:	10.1016/S0959-8049(11)72431-5